Side-by-side financials for AKBA and AZN. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AKBA | AZN |
|---|---|---|
| Market cap | - | $286.27 B |
| US-listed rank | - | #49 |
| Revenue (latest FY) | $236.20M | - |
| Net income (latest FY) | -$5.30M | - |
| Net margin | -2.2% | - |
| SEC filings | 868 | 1,004 |
Full pages: Akebia Therapeutics, Inc. and AstraZeneca PLC, or browse the full rankings.